Table 3.
Bayesian sparse logistic regression coefficient estimates and 90% posterior intervals for VTE outcome
| Biomarker | HGNC | Point estimate | Lower 90% PI | Upper 90% PI |
|---|---|---|---|---|
| Stromal cell–derived factor-1 (SDF-1) | CXCL12 | −0.2437 | −0.9260 | 0.0148 |
| Thyroid-stimulating hormone (TSH) | TSHB | −0.1796 | −0.8036 | 0.0146 |
| Monocyte chemotactic protein 4 (MCP-4) | CCL13 | −0.1182 | −0.7075 | 0.0208 |
| Interferon-inducible T-cell α chemoattractant (ITAC) | CXCL11 | 0.1013 | −0.0234 | 0.7182 |
| Growth hormone (GH) | GH1 | 0.0968 | −0.0203 | 0.5867 |
| Human epidermal growth factor receptor 2 (HER-2) | ERBB2 | 0.0436 | −0.0255 | 0.3507 |
| Interleukin-1 receptor type 1 (IL-1R1) | IL1R1 | 0.0342 | −0.0279 | 0.2484 |
| Pulmonary and activation-regulated chemokine (PARC) | CCL18 | −0.0341 | −0.2519 | 0.0270 |
| Myoglobin | MB | 0.0326 | −0.0278 | 0.2424 |
| MHC class I chain-related protein A (MICA) | MICA | 0.0321 | −0.0305 | 0.2226 |
| Human chorionic gonadotropin β (hCG) | CGB3 | 0.0315 | −0.0267 | 0.2269 |
| Folate receptor γ (FOLR3) | FOLR3 | 0.0294 | −0.0280 | 0.2024 |
| Heparin-binding EGF-like growth factor (HB-EGF) | HBEGF | 0.0290 | −0.0289 | 0.1978 |
| Superoxide dismutase 1, soluble (SOD-1) | SOD1 | 0.0283 | −0.0256 | 0.1947 |
| Carbonic anhydrase 9 (CA-9) | CA-9 | 0.0259 | −0.0245 | 0.1789 |
| Granulocyte colony-stimulating factor (G-CSF) | CSF3 | −0.0257 | −0.1770 | 0.0299 |
HGNC, human gene symbol; point estimate, mean posterior estimate of inverse normal transformed and standardized biomarker lower and upper 90% PIs for regression coefficient from the Markov chain Monte-Carlo; EGF, epidermal growth factor; MHC, major histocompatibility complex; PI, posterior interval.